PAI
Palo Alto Investors Portfolio holdings
AUM
$470M
This Quarter Return
+5.27%
1 Year Return
+2.57%
3 Year Return
+93.77%
5 Year Return
+190.64%
10 Year Return
+955.02%
AUM
$470M
AUM Growth
+$470M
(-11%)
Cap. Flow
-$44.8M
Cap. Flow
% of AUM
-9.53%
Top 10 Holdings %
Top 10 Hldgs %
75.24%
Holding
50
New
6
Increased
5
Reduced
16
Closed
5
Top Buys
| 1 |
Disc Medicine
IRON
|
$7.72M |
| 2 |
STAAR Surgical
STAA
|
$4.48M |
| 3 |
Avidity Biosciences
RNA
|
$3.38M |
| 4 |
Denali Therapeutics
DNLI
|
$3.35M |
| 5 |
CRISPR Therapeutics
CRSP
|
$2.17M |
Top Sells
| 1 |
Sarepta Therapeutics
SRPT
|
$13.4M |
| 2 |
Insmed
INSM
|
$12.3M |
| 3 |
Amicus Therapeutics
FOLD
|
$9.94M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
$8.29M |
| 5 |
AnaptysBio
ANAB
|
$4.62M |
Sector Composition
| 1 | Healthcare | 98.54% |
| 2 | Financials | 1.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Insmed
INSM
$28.8B
| $87.1M | 18.52% | 865,113 -122,040 | -12% | -$12.3M |
|
2
Acadia Pharmaceuticals
ACAD
$4.38B
| $55.3M | 11.76% | 2,563,209 -100,716 | -4% | -$2.17M |
|
|
3
BioMarin Pharmaceuticals
BMRN
$11.2B
| $46.2M | 9.83% | 840,470 -150,737 | -15% | -$8.29M |
|
|
4
Amicus Therapeutics
FOLD
$2.34B
| $32.1M | 6.84% | 5,610,513 -1,734,489 | -24% | -$9.94M |
|
5
United Therapeutics
UTHR
$13.8B
| $27.4M | 5.84% | 95,482 -9,746 | -9% | -$2.8M |
|
6
Biogen
BIIB
$19.4B
| $25.8M | 5.5% | 205,759 +836 | +0.4% | +$105K |
|
7
Alnylam Pharmaceuticals
ALNY
$58.5B
| $24.6M | 5.24% | 75,535 -7,953 | -10% | -$2.59M |
|
8
PTC Therapeutics
PTCT
$3.92B
| $19.9M | 4.22% | 406,469 +2,273 | +0.6% | +$111K |
|
|
9
AnaptysBio
ANAB
$569M
| $18M | 3.84% | 812,821 -207,892 | -20% | -$4.62M |
|
10
NovoCure
NVCR
$1.38B
| $17.1M | 3.64% | 962,396 -39,665 | -4% | -$706K |
|
|
11
STAAR Surgical
STAA
$1.36B
| $13.3M | 2.83% | 791,879 +266,862 | +51% | +$4.48M |
|
12
Agios Pharmaceuticals
AGIO
$2.19B
| $8.94M | 1.9% | 268,783 -7,795 | -3% | -$259K |
|
13
Prothena Corp
PRTA
$441M
| $7.74M | 1.65% | 1,274,753 -384,981 | -23% | -$2.34M |
|
|
14
Disc Medicine
IRON
$2.07B
| $7.72M | 1.64% | +145,691 | New | +$7.72M |
|
15
Align Technology
ALGN
$10.3B
| $7.15M | 1.52% | 37,772 | – | – |
|
16
Gossamer Bio
GOSS
$562M
| $7.06M | 1.5% | 5,739,013 -537,880 | -9% | -$662K |
|
17
eHealth
EHTH
$118M
| $6.86M | 1.46% | 1,577,850 -106,486 | -6% | -$463K |
|
18
Alkermes
ALKS
$4.78B
| $6.32M | 1.35% | 221,021 -492 | -0.2% | -$14.1K |
|
19
Iovance Biotherapeutics
IOVA
$807M
| $5.9M | 1.26% | 3,429,329 +218,015 | +7% | +$375K |
|
20
Syndax Pharmaceuticals
SNDX
$1.41B
| $4.16M | 0.89% | 444,367 | – | – |
|
|
21
Avidity Biosciences
RNA
$5.99B
| $3.38M | 0.72% | +118,886 | New | +$3.38M |
|
|
22
Denali Therapeutics
DNLI
$2.23B
| $3.35M | 0.71% | +239,809 | New | +$3.35M |
|
23
Mirum Pharmaceuticals
MIRM
$3.71B
| $3.29M | 0.7% | 64,700 | – | – |
|
24
Edwards Lifesciences
EW
$47.8B
| $3.09M | 0.66% | 39,473 | – | – |
|
25
Taysha Gene Therapies
TSHA
$797M
| $2.88M | 0.61% | 1,246,033 -173,435 | -12% | -$401K |
|